俊宏固肾生发丸品牌怎么样 申请店铺

我要投票 俊宏固肾生发丸在生发行业中的票数:544 更新时间:2025-07-03
俊宏固肾生发丸是哪个国家的品牌?「俊宏固肾生发丸」是 吉林省俊宏药业有限公司 旗下著名品牌。该品牌发源于吉林省通化市,由创始人张士俊在2001-09-04期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力俊宏固肾生发丸品牌出海!将品牌入驻外推网,定制俊宏固肾生发丸品牌推广信息,可以显著提高俊宏固肾生发丸产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

俊宏固肾生发丸怎么样

辉南县位于中药材资源丰富的长白山麓松花江畔,地处吉林省东南部,隶属通化市管辖,东南与靖宇县毗邻,西距梅河口市45公里,南与柳河县接壤,东与桦甸市相边,北与磐石市隔江相望,县城朝阳镇位于辉南县西北角部,素有“参鹿之乡,医药名城”之美誉。俊宏药业有限公司就位于县城东北部,辉南经济开发区内。

俊宏药业有限公司成立于1990年,注册资金5000万元,2001年由长春搬迁到辉南,并按GMP标准实施改造工程。于2003年初整体通过了国家药品GMP认证并投入正式生产。公司类型为民营有限责任公司,资产总额5.5亿元。公司占地面积21万平方米,建筑面积5.8万平方米,现有员210人,各类专业技术人员70余人,其中具有高级职称9人,职业药师7人。公司现有前处理提取车间、固体制剂车间、保健用品车间、中心化验室等四个车间和七个职能管理科室。有胶囊剂、片剂、颗粒剂、散剂、水丸、蜜丸、浓缩丸、水蜜丸、糊丸、中药饮片和贴膏剂、软膏剂、液体制剂等13个剂型,共有87个国药准字号中成药生产品种和33个吉卫健用字号保健用品生产品种,其中获国家中药保护品种1个。公司拥有完备的生产设备和精湛的工艺技术,是一个已通过新修订的国家药品GMP认证、以固体制剂为主体的现代化中成药制药和保健用品生产企业。

公司自成立以来一贯奉行以市场为导向,以产品为载体,以质量为生命的生产经营宗旨。按照现代化企业制度的要求,规范管理机制,强化营销策略,坚持内抓管理,外拓市场,以质量求生存,靠信誉求发展的经营理念。凭借高质量的产品和良好的商业信誉,已在全国大部分省市建立了自己的销售网络,产品销售量逐年增加,各项经济指标逐年增长。

公司把建设“规模强大,实力雄厚,效益显著”的科技创新型企业作为发展战略,已与省中医药研究院、吉大药学院等科研机构、大专院校建立了合作关系,成功开发了一系列新药特药,其中研制开发的保健用品产品种已获批号33个,目前已正式投产上市,公司将不断研制开发高科技新产品,以使企业实力不断增强,朝更高、更强的目标迈进,为医药行业的繁荣发展而做出贡献。


Huinan County is located on the Bank of Songhua River at the foot of Changbai Mountain, which is rich in traditional Chinese medicine resources. It is under the jurisdiction of Tonghua city. It is adjacent to Jingyu County in the southeast, 45km away from Meihekou city in the west, Liuhe County in the south, Huadian City in the East and Panshi City in the north. Chaoyang Town, located in the northwest corner of Huinan County, is known as the "hometown of shenlu and famous medical city". Junhong Pharmaceutical Co., Ltd. is located in Huinan Economic Development Zone in the north of the east of the county. Junhong Pharmaceutical Co., Ltd. was founded in 1990 with a registered capital of 50 million yuan. It was moved from Changchun to Huinan in 2001, and the transformation project was implemented according to GMP standards. At the beginning of 2003, it passed the national GMP certification and put into formal production. The company is a private limited liability company with total assets of RMB 550 million. The company covers an area of 210000 square meters, with a building area of 58000 square meters. There are 210 employees and more than 70 professional and technical personnel, including 9 with senior titles and 7 professional pharmacists. The company has four workshops and seven functional management departments, including pretreatment and extraction workshop, solid preparation workshop, health care supplies workshop, and central laboratory. There are 13 dosage forms including capsule, tablet, granule, powder, water pill, honey pill, concentrated pill, water honey pill, paste pill, Chinese herbal pieces and pastes, ointment, liquid preparation, etc. there are 87 production varieties of Chinese patent medicine under the state drug registration number and 33 production varieties of health care products under the Ji Wei Jian use number, of which one is under the state protection of traditional Chinese medicine. The company has complete production equipment and exquisite technology. It is a modern Chinese patent medicine and health care products manufacturer that has passed the newly revised national GMP certification and takes solid preparations as the main body. Since its establishment, the company has always adhered to the production and operation tenet of market-oriented, product-oriented and quality-oriented. According to the requirements of modern enterprise system, standardize the management mechanism, strengthen the marketing strategy, adhere to the business philosophy of internal management, external market expansion, survival by quality and development by reputation. With high-quality products and good business reputation, we have established our own sales network in most provinces and cities of the country. The sales volume of products increases year by year, and the economic indicators increase year by year. The company takes the construction of a scientific and technological innovation enterprise with "strong scale, strong strength and remarkable benefits" as its development strategy. It has established cooperative relations with scientific research institutions and colleges and universities such as Provincial Institute of traditional Chinese medicine, Jida College of medicine, etc., and has successfully developed a series of new drugs and specialty drugs, including 33 batches of health care products, which have been officially put into production and listed. The company will We will continue to develop new high-tech products, so as to enhance the strength of the enterprise, move towards a higher and stronger goal, and contribute to the prosperity and development of the pharmaceutical industry.

本文链接: https://brand.waitui.com/e70e8902c.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

医药、北交所相关产品领跑,主动权益类基金上半年平均收益6.78%

公募基金上半年交出亮眼答卷。Choice数据显示,主动权益类基金上半年平均收益为6.78%,超八成实现正收益。其中,347只基金收益在20%以上,50只收益超过40%,更有11只收益超60%。中信建投北交所精选两年定开混合基金夺得“半程冠军”,收益超80%。重仓创新药的基金业绩也较为亮眼,在主动权益类基金业绩前十强中占据六席。展望下半年,多家基金公司表示,市场结构性机会涌现,当前投资策略应更积极一些。(上证报)

2小时前

私募调研聚焦小盘成长风格,预判结构性行情主导市场

随着近期A股市场震荡上行,私募机构的调研图谱清晰折射出对结构性机会的深度挖掘。第三方机构最新监测数据显示,6月份私募机构调研A股上市公司频次高达1769次,751家私募机构调研涉足28个申万一级行业中的387只个股。其中,电子、医药生物、机械设备三大行业成为“调研主阵地”,而小市值成长股更成为机构扎堆调研的对象。展望后市,多家一线私募认为,结构性行情将主导市场,但不同机构的策略侧重则有所不同。(中证网)

2小时前

华泰证券:关注科技公司港股二次上市的投资机会

36氪获悉,华泰证券研报表示,对拟上市企业而言,二次上市可带来多元化的融资渠道,并借助港股“闪电配售”等机制提升融资效率,增强国际市场认知度,助力其全球化布局;对港股投资者而言,短期内有望把握港股与A股之间的折价套利机会,长期则将受益于恒生科技指数成分质量的显著提升,从而吸引更多国际资金入场;对A股投资者而言,这不仅意味着A股公司的投资价值得到国际认可,也为A股核心科技资产提供了新的国际估值参照,进而可能引发整体估值框架的重塑。

2小时前

“不扎堆”也能赢,基金经理练就多元配置硬实力

上半年主动权益类基金业绩排名前二十的基金大部分是主题投资选手:创新药、北交所、机器人……甚至有基金的名称看似是全市场选股,但前十大重仓股均来自单一热门赛道。与此同时,记者梳理发现,仍有不少基金经理在坚守多元布局的前提下,为投资者贡献了稳健的收益。成长派基金经理高楠管理的永赢融安和永赢睿信均在上半年取得了超过25%的回报率。通过观察两只基金的投资策略,高楠一方面参与了创新药、半导体、IT等成长性较强的科创板块,另一方面在家居、电源设备等领域进行布局。(中证网)

2小时前

6月份私募机构调研热情高涨,电子和医药生物板块受追捧

私募排排网最新统计数据显示,6月份,私募机构调研A股上市公司热情高涨。当月共有751家私募机构参与调研,覆盖28个申万一级行业中的387家上市公司,合计调研次数达到1769次,展现出机构投资者对A股市场的高度关注。从行业分布来看,电子、医药生物、机械设备、计算机等行业成为私募机构调研的重点领域。其中,电子行业以获私募机构调研275次位居榜首,涉及56家公司;医药生物行业紧随其后,获调研266次,覆盖41家公司;机械设备、计算机行业分别获得调研234次和213次,位居第三位、第四位。(证券日报)

2小时前

本页详细列出关于俊宏固肾生发丸的品牌信息,含品牌所属公司介绍,俊宏固肾生发丸所处行业的品牌地位及优势。
咨询